Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Dec 16, 2022; 10(35): 12804-12811
Published online Dec 16, 2022. doi: 10.12998/wjcc.v10.i35.12804
Published online Dec 16, 2022. doi: 10.12998/wjcc.v10.i35.12804
Principle and progress of radical treatment for locally advanced esophageal squamous cell carcinoma
Xiao-Fei Zhang, Kuai-Le Zhao, Wei-Xin Zhao, Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China
Xiao-Fei Zhang, Kuai-Le Zhao, Wei-Xin Zhao, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
Xiao-Fei Zhang, Kuai-Le Zhao, Wei-Xin Zhao, Shanghai Clinical Research Center for Radiation Oncology Shanghai Key Laboratory of Radiation Oncology, Shanghai 200032, China
Pei-Yi Liu, Department of Orthopedics, Tongren Hospital, School of Medicine Shanghai Jiao Tong University, Shanghai 200336, China
Shu-Juan Zhang, Department of Oncology, The Second People's Hospital of Kashgar, Kashgar 844000, Xinjiang Uygur Autonomous Region, China
Author contributions: Zhang XF, Liu PY and Zhang SJ contribute equally; Zhao KL and Zhao WX substantial contributions to the conception and design of the study; Zhang XF and Liu PY draft the article or revising it critically for important intellectual content, acquisition of the data and analysis and interpretation of the data; Zhang SJ approved the final version to be published.
Supported by Key Clinical Specialty Project of Shanghai.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Wei-Xin Zhao, MD, Department of Radiation Oncology, Fudan University Shanghai Cancer Center, No. 270 Dongan Road, Xuhui, Shanghai 200032, China. zwx_zhxf@163.com
Received: August 1, 2022
Peer-review started: August 1, 2022
First decision: September 5, 2022
Revised: September 19, 2022
Accepted: November 10, 2022
Article in press: November 10, 2022
Published online: December 16, 2022
Peer-review started: August 1, 2022
First decision: September 5, 2022
Revised: September 19, 2022
Accepted: November 10, 2022
Article in press: November 10, 2022
Published online: December 16, 2022
Core Tip
Core Tip: For the radical treatment of esophageal squamous cell carcinoma, the effect of radiotherapy and chemotherapy is equivalent to that of surgery. In the era of immunization, it is recommended to use involved field irradiation. Fluorouracil plus cisplatin regimen is the standard chemotherapy regimen, FOLFOX regimen and paclitaxel plus fluorouracil regimen are optional concurrent chemotherapy regimens. The toxic and side effects of different chemotherapy regimens are very different, which can be selected according to the actual situation of patients.